There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop.

Learn more about your ad choices. Visit megaphone.fm/adchoices